CannTrust (TRST) Price Target Increased to $9.50 by Analysts at Canaccord Genuity

CannTrust (CNSX:TRST) had its price target increased by Canaccord Genuity from $7.25 to $9.50 in a research report released on Monday.

Shares of CannTrust (CNSX:TRST) traded up C$0.37 during trading hours on Monday, reaching C$7.52. 917,237 shares of the company were exchanged, compared to its average volume of 18,422. CannTrust has a 52 week low of C$1.69 and a 52 week high of C$7.75.

In other news, Director Mitchell J. Sanders sold 20,000 shares of the company’s stock in a transaction dated Friday, November 24th. The stock was sold at an average price of C$7.70, for a total value of C$154,000.00.

WARNING: “CannTrust (TRST) Price Target Increased to $9.50 by Analysts at Canaccord Genuity” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/canntrust-trst-price-target-increased-to-9-50-by-analysts-at-canaccord-genuity.html.

About CannTrust

CannTrust Holdings Inc is a Canada-based company, which produces pharmaceutical-grade medical cannabis for patients. The Company is a federally regulated licensed producer of medical cannabis products. The Company operates a hydroponic facility and an onsite laboratory for testing and research on the medical use of cannabis.

Receive News & Ratings for CannTrust Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply